Our goal is to help each patient improve their overall health, mobility, and quality of life through personalized and effective weight management strategies
These agents are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, based on findings from preclinical studies ( Treatment cessation should also be considered in patients who develop gallbladder complications, such as acute cholecystitis
Key Takeaways Starting dose: 2 mg once weekly for 4 weeks Titration pace: Increase every 4 weeks: 2 4 8 12 mg Maximum dose: 12 mg weekly (Phase 2/3 clinical trial protocol) Total ramp-up: ~16 weeks to reach maximum dose Mechanism: Triple agonist (GLP-1 + GIP + Glucagon), the only triple-agonist in late-stage trials Weight loss: Up to 24.2% at 48 weeks (Phase 2) and 28.7% at 68 weeks (Phase 3 TRIUMPH-4) GLP-3 Retatrutide Dosage Chart Free printable reference chart showing the retatrutide (GLP-3) clinical trial titration schedule from 2 mg to 12 mg weekly
Back Holst, JJ (2022) 'Discovery of the GI effects of GLP-1: An historical perspective', Digestive Diseases and Sciences , 67, 2716-20
These drugs also slow down the emptying of the stomach and interact with GLP-1 receptors in the brain to tamp down hunger
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
